HuMedix Holds "Elravie Russia Academy"

Huons Group's HuMedix held an on-site communication meeting, inviting its Russian partner company and local medical professionals, ahead of the launch of its hyaluronic acid (HA) filler products in Russia. On the previous day (the 6th), HuMedix hosted the "Elravie Russia Academy," inviting executives and employees from its distribution partner Bella-Systech, as well as key local medical professionals from Russia, the company announced on the 7th. To commemorate the upcoming entry of its HA fillers into the Russian market next year, HuMedix organized this event to strengthen its partnership and to showcase the superior competitiveness of its products to local medical professionals. On the morning of the event, the visiting group attended a theoretical lecture and live demonstration of the "Elravie Premier Filler" at Gangnam Beauty Bar Plastic Surgery Clinic. Kim Eunyeon, the clinic's director and the event's speaker, delivered a lecture on "the rheological properties and sterilization p

Bio Health

11.07 10:37

U.S. Grants National Priority Voucher Benefits to Obesity Treatments Including Wegovy

The U.S. Food and Drug Administration (FDA) announced on November 6 (local time) that Eli Lilly, Novo Nordisk, and others will receive national priority voucher benefits for obesity and diabetes treatments. Through this benefit, the price of Eli Lilly's Zepbound and the under-review Orforglipron will be reduced from an average of $1,086 (approximately 1.58 million won) per month to $346 (about 500,000 won) per month. The prices of Novo Nordisk's Ozempic and Wegovy will also drop to $350 (about 510,000 won) per month when purchased through 'TrumpRx', down from $1,000 (about 1.45 million won) and $1,350 (about 1.96 million won) per month, respectively. These products are expected to be available for purchase on 'TrumpRx', a new website to be launched within the year that will allow consumers to buy pharmaceuticals at discounted prices. In addition, Eli Lilly and Novo Nordisk have reportedly pledged new investments of $27 billion (about 39.17 trillion won) and $10 billion (about 14.51 tri

Bio Health

11.07 09:52

CGBio Medtech's Spinal Implant 'UniSpace' Receives FDA Clearance

CGBio Medtech, a company specializing in the research and manufacturing of orthopedic implants, announced on November 7 that its spinal fusion device, "UniSpace® TPLIF Cage (Lumbar Cage)," has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The newly approved lumbar "UniSpace" device was designed to be compatible with CGBio's next-generation bone substitute, "NOVOSIS PUTTY." With NOVOSIS PUTTY having received Investigational Device Exemption (IDE) approval for clinical trials from the FDA in April of this year, the earlier FDA clearance of UniSpace further increases the likelihood of clinical success for NOVOSIS PUTTY in the future. UniSpace is a spinal implant structure (cage) that is inserted between vertebrae after removal of a damaged disc during the treatment of degenerative spinal diseases. It enhances stability and supports bone regrowth and fusion. The device utilizes titanium 3D printing technology to create a dual pore structure similar to human ca

Bio Health

11.07 09:19

Trump Reaches Agreement to Lower Prices of Obesity Drugs Like Wegovy: "Down to $250-$350"

The prices of major obesity treatment drugs, such as Wegovy, which have been sold for over $1,000 (approximately 1.5 million won) per month in the United States, are expected to be reduced to the range of $250 to $350 (approximately 360,000 to 500,000 won). On the 6th (local time), President Donald Trump announced at the White House that Eli Lilly, the pharmaceutical company behind Zepbound, and Novo Nordisk, the producer of Wegovy, have agreed to lower the prices of obesity treatment drugs in the United States. President Trump stated, "The two pharmaceutical companies have agreed to provide obesity medications to the United States based on the most-favored-nation standard," adding, "The price of Wegovy will drop from $1,350 per month to $250, and Zepbound will be reduced from $1,080 per month to $346." He further explained that, for Medicare recipients?seniors aged 65 and older and certain individuals with disabilities?as well as Medicaid recipients?those eligible for low-income medi

Bio Health

11.07 06:05

Ligakem Bio Wins Two Categories at the World ADC Awards

Ligakem BioScience Co., Ltd. (Ligakem Bio) announced that at the 12th Annual World ADC Awards held in San Diego, USA, on the 5th (local time), its HER2 ADC "IKS014 (LCB14)," which was licensed out to Iksuda Therapeutics, won the top prize in the "Most Promising ADC to Watch" category. Additionally, the company was named a winner in the "Best ADC Platform Technology" category. This marks the first time that a clinical drug developed using Ligakem Bio's ADC platform has received this award. This recognition by global experts demonstrates that Ligakem Bio is evolving from being a platform-centered company to one focused on clinical pipelines. At the ADC Awards, the "Most Promising ADC to Watch" category is given to the most promising ADC clinical candidate in the early clinical stage, with Phase 1 data disclosed. This year, among the five final candidates in this category, two programs were based on Ligakem Bio's ADC platform technology: the HER2 ADC "IKS014" and the ROR1 ADC "CS5001 (LC

Bio Health

11.06 16:03

Asan Medical Center Transfers 'Stem Cell Technology' for Intractable Immune Disease Treatment to Pharmicell

Asan Medical Center in Seoul has transferred its stem cell therapy technology, developed for the treatment of intractable immune diseases, to a biotechnology company. The research team led by Professor Dongmyung Shin of the Department of Cell and Genetic Engineering and Professor Seunghoo Kim of the Department of Biochemistry and Molecular Biology at Ulsan University College of Medicine, Asan Medical Center, announced on November 6 that they have signed a contract to transfer their patented stem cell culture technology to Pharmicell Co., Ltd. This technology simultaneously enhances the antioxidant capacity, engraftment rate, and stem cell characteristics of stem cells. This stem cell culture technology enables the production of functionally enhanced mesenchymal stem cells (hereafter referred to as PFO-MSCs). Mesenchymal stem cells can differentiate into various tissues such as cartilage, bone, and fat, playing a crucial role in tissue regeneration and immune regulation. To develop PFO

Bio Health

11.06 15:54

Numerous Genetic Factors for Alzheimer's Identified in Koreans... Foundation Laid for Precision Personalized Treatment

Numerous new genes involved in the onset of Alzheimer's disease among Koreans have been identified. The National Institute of Health under the Korea Disease Control and Prevention Agency announced on November 6 that, based on a cohort of elderly dementia patients, it has analyzed the genetic information and brain imaging data of Korean dementia patients and discovered new genetic factors involved in the development of Alzheimer's disease, including SORL1, APCDD1, and DRC7. The institute also proposed a "cumulative effects model," which explains how multiple genetic factors act together to cause the disease. Since 2021, the agency has been collecting long-term data by tracking healthy individuals, those with mild cognitive impairment, and dementia patients in Korea, establishing the "Elderly Dementia Patient Cohort (BRIDGE-LLOD)." It is also conducting the "Brain Disease Research Infrastructure Project," which links brain disease cohort data in collaboration with domestic universities a

Bio Health

11.06 15:34

Dongkook Pharmaceutical Participates in 'CPHI 2025'... Expanding Global Network

Dongkook Pharmaceutical announced on the 6th that it participated in 'CPHI Worldwide 2025,' the world's largest pharmaceutical and bio industry exhibition, held in Frankfurt, Germany from October 28 to 30. 'CPHI Worldwide' is a flagship event for the pharmaceutical and bio industry, held annually in major European countries. This year’s event brought together more than 2,400 pharmaceutical and bio companies and over 62,000 industry professionals from around 160 countries worldwide. Dongkook Pharmaceutical operated an independent booth, focusing on promoting the technological excellence of its long-acting injectable (Depot) products, 'Lorelindepho' and 'Octrinlar,' both utilizing its proprietary Microsphere technology. The company also highlighted the superior efficacy and safety data of its improved drug for benign prostatic hyperplasia, 'Uresco Tab' (a combination of dutasteride and tadalafil), based on Phase 3 clinical trial results, emphasizing the product’s differentiation and mark

Bio Health

11.06 14:29

Pfizer Acquires Carmot Therapeutics for $10 Billion, Wins Obesity Drug Acquisition Battle

HuMedix Holds "Elravie Russia Academy"

U.S. Grants National Priority Voucher Benefits to Obesity Treatments Including Wegovy

CGBio Medtech's Spinal Implant 'UniSpace' Receives FDA Clearance

Trump Reaches Agreement to Lower Prices of Obesity Drugs Like Wegovy: "Down to $250-$350"

Ligakem Bio Wins Two Categories at the World ADC Awards

Asan Medical Center Transfers 'Stem Cell Technology' for Intractable Immune Disease Treatment to Pharmicell

Numerous Genetic Factors for Alzheimer's Identified in Koreans... Foundation Laid for Precision Personalized Treatment

Dongkook Pharmaceutical Participates in 'CPHI 2025'... Expanding Global Network

Special Coverage

In the News